Akeso’s Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
HONG KONG, March 17, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasopharyngeal cancer (NPC) in combination with chemotherapy. Previously, penpulimab was approved for use as a third-line treatment for advanced NPC. With...
HanAll Biopharma Announces Orphan Drug Designation for Batoclimab in Japan for Active Thyroid Eye Disease
Batoclimab receives Orphan Drug Designation in Japan, advancing treatment for active Thyroid Eye Disease (TED). Batoclimab, subcutaneous formulation, offers the potential for at-home administration, improving patient convenience and accessibility. Phase 3 study to confirm the potential of batoclimab to address unmet needs of patients with TED in process, with top-line results expected...
Skyhawk Therapeutics Presents at Huntington’s Disease Youth Organization HDYO International Congress 2025
Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO International Congress in Prague, Czech Republic. BOSTON, March 15, 2025 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to...
QNET Scores Triple Silver at the Stevie® Awards for Impact in Sustainability & Innovation
HONG KONG, March 15, 2025 /PRNewswire/ -- QNET, a global lifestyle and wellness direct-selling company, has been recognized with three Silver Stevie® Awards, highlighting its impact in environmental sustainability, corporate social responsibility, and product innovation. The accolades, presented at the Middle East and North Africa Stevie Awards, honor the QNET Green Legacy Programme, its fight against plastic pollution through the...
Florbetaben (18F) Injection (Neuraceq®) Set to Launch at St. Teresa’s Hospital in Hong Kong in March 2025
Innovative Imaging Solution to Enhance Alzheimer's Disease Diagnosis and Patient Care in the Region BOSTON, March 14, 2025 /PRNewswire/ -- Life Molecular Imaging (LMI) and St. Teresa's Hospital are pleased to announce that Florbetaben (18F) Injection (brand name: Neuraceq®) will be available in Hong Kong from St. Teresa's Hospital by March 2025. Neuraceq® is...
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma
WOBURN, Mass., March 14, 2025 /PRNewswire/ -- Azurity Pharmaceuticals ("Azurity") announced today the successful completion of its acquisition of Covis Group S.à r.l. ("Covis") from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity. This strategic acquisition reinforces Azurity's leadership in branded pharmaceuticals, harnessing the complementary strengths of...
China’s First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease
SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SYCUME® (teprotumumab N01, a recombinant anti-insulin-like growth factor 1 receptor...
Accropeutics Secured $12 Million in Series B Plus Financing
Approximately $12 million additional financing led by Shenzhen Capital Group (SCGC), with participation from existing investor Morningside Ventures, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST). Cash runway extended into the second half of 2026 NEW YORK and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology...
Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma
HONG KONG, March 14, 2025 /PRNewswire/ -- Teva Hong Kong ("Teva"), has announced a strategic partnership with Kerry Pharma, the subsidiary of Kerry Logistics Network Ltd ("KLN"). Leveraging Kerry Pharma's extensive logistics (fourth-party logistics, 4PL) distribution capabilities, this collaboration aims to enhance Teva's pharmaceutical distribution system in Hong Kong, Macau, and the Greater Bay Area, ensuring a stable supply of...
Beyond Claims: How Kuky Helps Health Insurers Enhance Community Well-Being
SYDNEY, March 14, 2025 /PRNewswire/ -- In 2022-23, Australia spent more than $8 billion on state and territory specialised mental health services. Already staggering, the amount does not include Australian Capital Territory jurisdictional or non-Commonwealth numbers, which were not available when the government released the national data in February 2025. The country's total mental health expenditure for 2022-23 stood...
